The rational for combining these agents was that HDAC inhibitors had been demonstrated to regulate the expression of multiple apoptotic mediators and induce mitochondria-dependent apoptosis in various malignant tumor cells, such as melanoma cells, osteosarcoma cells and leukaemia cells [17-19]. This evidence concerns the gene HDAC9 and leukemia.